A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Phase of Trial: Phase III
Latest Information Update: 27 Mar 2018
At a glance
- Drugs Budesonide/formoterol (Primary) ; Budesonide; Formoterol
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics; Registrational; Therapeutic Use
- Acronyms telos
- Sponsors AstraZeneca AB; Pearl Therapeutics
- 21 Mar 2018 Status changed from active, no longer recruiting to completed.
- 09 Feb 2018 This trial was completed Czech Republic (end date: 2017-12-01), according to European Clinical Trials Database.
- 15 Jan 2018 This trial was completed in Poland (end date: 2017-12-01), according to European Clinical Trials Database.